why choose us

First received: January 30, 2023

Clinical Trial: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Locally Advanced Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

Brief Summary: This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion.The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types.The study drug, TNG462, is a selective PRMT5 inhibitor administered orally.The study is planned to treat up to 159 participants.

Read more